Shaji K. Kumar
Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.
Shaji Kumar is a haematologist leading myeloma clinical research at Mayo Clinic Rochester. Chaired BELLINI (venetoclax in t(11;14) myeloma), co-authored the IMWG response and MRD criteria, and leads ECOG-ACRIN myeloma trials.
Pages like this
not linked directly; found by shared links- PersonS. Vincent Rajkumar
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Mayo Clinic, Multiple myeloma.
- IdeaMRD-guided treatment-free intervals in myeloma
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD / molecular residual disease testing, Multiple myeloma.
- PersonMark R. Litzow
- InstitutionMayo Clinic Comprehensive Cancer Center – Arizona
Shares Mayo Clinic, Multiple myeloma.
- Key paperPERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares MRD / molecular residual disease testing, Multiple myeloma.
- Key paperCEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD / molecular residual disease testing, Multiple myeloma.
- CollectionMultiple Myeloma Research Foundation (MMRF)
Shares MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), Multiple myeloma.